Department of Nuclear Medicine, CERIMED, La Timone University Hospital, Aix-Marseille University, Marseille, France.
Department of Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), IPHC, UMR 7178, University Hospitals of Strasbourg, CNRS/University of Strasbourg, Strasbourg, France.
Q J Nucl Med Mol Imaging. 2022 Jun;66(2):141-147. doi: 10.23736/S1824-4785.22.03450-1. Epub 2022 Mar 28.
6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (F-DOPA) PET/CT can be a useful tool for the detection of different neuroendocrine tumors (NETs). The main determinants of F-DOPA uptake and retention by NETs are related to expression of LAT1/LAT2 transporters, expression and activity of AADC and biochemical phenotype, all being intimately inter-connected to their embryological origin. In order to improve sensitivity of F-DOPA PET, it is of main importance to perform indivisualized imaging protocols across primaries. This review provides a practical approach for performing well-tailored imaging protocols and describes the clinical value of the recommended radiopharmaceuticals.
6-[18F]-L-氟代-L-3,4-二羟基苯丙氨酸（F-DOPA）PET/CT 可作为检测不同神经内分泌肿瘤（NETs）的有用工具。NETs 对 F-DOPA 的摄取和保留的主要决定因素与 LAT1/LAT2 转运体的表达、AADC 的表达和活性以及生化表型有关，所有这些都与它们的胚胎起源密切相关。为了提高 F-DOPA PET 的灵敏度，对原发性肿瘤进行个体化成像方案至关重要。本综述提供了一种实用的方法来制定量身定制的成像方案，并描述了推荐放射性药物的临床价值。
